Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294), a pharmaceutical company based in China, has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its Category 1 drug, fotagliptin. This drug is intended to improve blood sugar control in adult patients with type 2 diabetes, and can be used as a monotherapy or in combination with other treatments such as metformin when it alone is not sufficient to effectively control blood sugar.
Fotagliptin, classified as a dipeptidyl peptidase-4 (DPP-4) inhibitor, functions by inhibiting the activity of DPP-4, which reduces the hydrolysis of intestinal stimulating hormones by DPP-4. This action leads to an increase in the plasma concentration of active forms of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), subsequently enhancing insulin release in a glucose-dependent manner while reducing glucagon levels and lowering blood sugar. The drug is noted for its rapid oral absorption, prolonged effect, high selectivity, and favorable safety profile.- Flcube.com
